Shields M J, Kubota R, Hodgson W, Jacobson S, Biddison W E, Ribaudo R K
Laboratory of Immune Cell Biology, NCI, National Institutes of Health, Bethesda, Maryland 20892-1152, USA.
J Biol Chem. 1998 Oct 23;273(43):28010-8. doi: 10.1074/jbc.273.43.28010.
The ability to directly load cell surface major histocompatibility complex (MHC) class I molecules with peptides provides a potentially powerful approach toward the development of vaccines to generate cell-mediated immunity. We demonstrate that exogenous beta2-microglobulin (beta2m) stabilizes human cell surface MHC I molecules and facilitates their loading with exogenous peptides. Additionally, using three-dimensional crystal structures and known interaction sites between MHC I heavy chains and beta2m, we engineered variants of human beta2m (hbeta2m) with a single serine substitution at residue 55. This alteration was predicted to promote hydrophobic interactions at the MHC I heavy chain/beta2m interface and displace an ordered water molecule. Compared with hbeta2m, the serine to valine substitution at residue 55 had improved ability to bind to cell surface HLA-A1, HLA-A2, and HLA-A3 molecules, facilitate exogenous peptide loading, and promote recognition by peptide-specific T cells. The inclusion of hbeta2m or higher affinity variants when pulsing cells with MHC-restricted peptides increases the efficiency of peptide loading 50-80-fold. Therefore, the inclusion of hbeta2m in peptide-based vaccines may increase cell surface antigen densities above thresholds that allow recognition of peptide antigens by the immune system, particularly for cryptic, subdominant, or marginally antigenic peptides.
直接用肽加载细胞表面主要组织相容性复合体(MHC)I类分子的能力为开发能产生细胞介导免疫的疫苗提供了一种潜在的强大方法。我们证明,外源性β2-微球蛋白(β2m)可稳定人类细胞表面MHC I类分子,并促进其与外源性肽的加载。此外,利用MHC I重链与β2m之间的三维晶体结构和已知相互作用位点,我们设计了人类β2m(hβ2m)的变体,其在第55位残基处有一个丝氨酸取代。预计这种改变会促进MHC I重链/β2m界面处的疏水相互作用,并取代一个有序水分子。与hβ2m相比,第55位残基处丝氨酸到缬氨酸的取代具有更强的结合细胞表面HLA-A1、HLA-A2和HLA-A3分子的能力,促进外源性肽加载,并促进肽特异性T细胞的识别。在用MHC限制性肽脉冲处理细胞时加入hβ2m或更高亲和力的变体,可使肽加载效率提高50至80倍。因此,在基于肽的疫苗中加入hβ2m可能会使细胞表面抗原密度增加到高于免疫系统识别肽抗原的阈值,特别是对于隐蔽的、亚显性的或边缘性抗原性肽。